🫀 Foxglove, Frailty, and HFrEF — Digitoxin in Advanced Heart Failure
Dr RR Baliga's "Got Knowledge Doc" Podkast
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
🚨 New RCT Alert from the NEJM!
Can an old 💊 make a comeback in modern 💓 failure care?
📌 The DIGIT-HF trial showed that digitoxin, a cardiac glycoside with hepatic clearance, reduced the combined endpoint of all-cause death or HF hospitalization in HFrEF patients on contemporary guideline-directed therapy — including ARNI, beta-blockers, MRAs & SGLT2i.
🩺 HR = 0.82; p = 0.03 📉
👩⚕️ Safe in CKD, consistent benefit in women.
⚠️ Serious AEs slightly higher (4.7% vs 2.8%)
📥 NNT = 22.
💡Is it time to reconsider digitoxin in advanced HFrEF?
#CardioTwitter #HFrEF #HeartFailure #Digitoxin #NEJM #Cardiology #SGLT2i #GuidelineTherapy